List of GLP-1 Medications: Every FDA-Approved Option in 2026

List of GLP-1 Medications: Every FDA-Approved Option in 2026

By Dr. Onikepe Adegbola, MD PhD

Patients ask me regularly: "What are all the GLP-1 medications?" The class has expanded significantly since exenatide hit the market in 2005, and keeping track of what's available — and what each one is approved for — has become a legitimate challenge. This is the complete list of GLP-1 medications currently FDA-approved in the United States, along with the clinical context you need to understand the differences between them.

The Complete List of GLP-1 Medications

Below is every GLP-1 receptor agonist with current FDA approval. I've organized them by active ingredient, since some molecules appear under multiple brand names for different indications.

Semaglutide

Semaglutide is arguably the most well-known GLP-1 agonist. It's available in three distinct formulations:

• Ozempic (injectable semaglutide): Approved for type 2 diabetes. Dosed once weekly via subcutaneous injection. Available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses. Also approved for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.
• Wegovy (injectable semaglutide): Approved for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity. Also approved for cardiovascular risk reduction regardless of diabetes status. Same molecule as Ozempic, higher maximum dose (2.4 mg weekly).
• Rybelsus (oral semaglutide): Approved for type 2 diabetes. Taken as a daily tablet — the first oral GLP-1 agonist. Available in 3 mg, 7 mg, and 14 mg doses. Must be taken on an empty stomach with no more than 4 oz of plain water, then wait 30 minutes before eating or drinking anything else.

Tirzepatide

Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two incretin receptors rather than one. This dual mechanism appears to produce stronger effects on both glucose control and weight loss compared to pure GLP-1 agonists in head-to-head trials.

• Mounjaro (tirzepatide injection): Approved for type 2 diabetes. Dosed once weekly. Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses.
• Zepbound (tirzepatide injection): Approved for chronic weight management. Same molecule as Mounjaro, same doses, separate brand name and indication.

Liraglutide

Liraglutide was one of the earlier GLP-1 agonists and remains in widespread use:

• Victoza (liraglutide): Approved for type 2 diabetes in adults and children ≥10 years. Daily subcutaneous injection. Doses of 0.6 mg, 1.2 mg, and 1.8 mg.
• Saxenda (liraglutide): Approved for chronic weight management. Higher dose (3 mg daily) than Victoza. Also approved for adolescents aged 12-17 with obesity.

Dulaglutide

• Trulicity (dulaglutide): Approved for type 2 diabetes. Once-weekly injection. Available in 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg doses. Also demonstrated cardiovascular benefit in the REWIND trial.

Exenatide

• Byetta (exenatide): The original GLP-1 agonist, approved in 2005 for type 2 diabetes. Twice-daily injection. Less commonly prescribed now due to the inconvenience of the dosing schedule.
• Bydureon BCise (exenatide extended-release): Once-weekly version of exenatide. 2 mg dose. Easier dosing but generally considered less potent than newer GLP-1 options.

Lixisenatide

• Adlyxin (lixisenatide): Approved for type 2 diabetes. Once-daily injection. Primarily affects postprandial (post-meal) glucose. Less commonly used as monotherapy — more often seen in the combination product Soliqua.

Combination Products

Several GLP-1 agonists are available in fixed-dose combinations with basal insulin:

• Soliqua (lixisenatide + insulin glargine): Combines a GLP-1 agonist with long-acting insulin in a single daily injection. For type 2 diabetes patients who need both.
• Xultophy (liraglutide + insulin degludec): Similar concept — combines liraglutide with long-acting insulin degludec. Once-daily injection for type 2 diabetes.

How to Make Sense of the List of GLP-1 Medications

With this many options, the obvious question is: which one should you take? The answer depends on several factors that your prescriber will weigh:

• Indication: Are you treating diabetes, managing weight, or both? Not all GLP-1 medications are approved for weight loss. As of now, only Wegovy, Zepbound, and Saxenda carry that specific indication.
• Delivery preference: Injection or oral? Rybelsus is the main oral option, though it requires strict fasting protocols. Most others are injectable.
• Dosing frequency: Once daily versus once weekly matters to patients. Weekly options (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon) are generally preferred for convenience.
• Efficacy: In head-to-head trials, tirzepatide (Mounjaro/Zepbound) and high-dose semaglutide (Wegovy) produce the most weight loss. But individual responses vary considerably.
• Insurance coverage: Often the deciding factor. Many insurers cover one GLP-1 but not another, or cover the diabetes indication but deny the weight loss indication. Prior authorization requirements vary.

Emerging GLP-1 Medications on the Horizon

The list of GLP-1 medications will keep growing. Several pipeline drugs are in late-stage clinical trials or under FDA review:

• Orforglipron: An oral non-peptide GLP-1 agonist from Eli Lilly. Unlike Rybelsus, it doesn't require the strict fasting protocol. Phase 3 trials show strong weight loss results.
• Survodutide: A dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim. Being developed for MASH (fatty liver disease) and obesity.
• Retatrutide: A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed up to 24% body weight loss at 48 weeks. Lilly's phase 3 program is underway.
• CagriSema: A combination of semaglutide and cagrilintide (an amylin analog) from Novo Nordisk. Designed to produce greater weight loss than semaglutide alone.

Supporting Your GLP-1 Journey

Regardless of which medication on this list of GLP-1 medications you end up taking, the side effect profiles overlap substantially. GI symptoms — nausea, constipation, reduced appetite, acid reflux — are common across the class. Nutritional deficiencies become a real risk when food intake drops dramatically.

I formulated Casa de Sante GLP-1 supplements to address these gaps. The line includes digestive enzymes, probiotics, protein supplements, and vitamin complexes — all low FODMAP and designed for the GI sensitivity that GLP-1 patients commonly experience. Supporting your body nutritionally isn't optional on these medications. It's foundational.

Understanding the Difference Between GLP-1 Agonists and GLP-1-Based Medications

A note on terminology, because it causes confusion. When people search for a list of GLP-1 medications, they usually mean "drugs in the incretin class used for diabetes or weight loss." But not everything on this list is a pure GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist. The combination products (Soliqua, Xultophy) include insulin alongside the GLP-1 component. And the pipeline drugs include triple agonists and amylin analogs paired with semaglutide.

The term "GLP-1 medication" has become shorthand for the entire incretin-based drug class, even when the mechanism extends beyond GLP-1 receptor agonism alone. This matters clinically because the dual and triple agonists aren't just "more GLP-1" — they produce qualitatively different metabolic effects through additional receptor pathways. Patients switching from a pure GLP-1 agonist to tirzepatide, for example, may experience different side effect patterns and different timelines for efficacy.

The bottom line: ask your prescriber not just "which GLP-1 should I take" but "which specific mechanism of action is right for my situation." The answer might be pure GLP-1, dual GLP-1/GIP, or eventually a triple agonist — and those distinctions are clinically meaningful.

Frequently Asked Questions

What is the strongest GLP-1 medication for weight loss?

In head-to-head clinical data, tirzepatide (Zepbound/Mounjaro) at higher doses has produced the most weight loss, followed closely by semaglutide 2.4 mg (Wegovy). However, individual responses vary, and the "strongest" medication isn't always the best fit for a particular patient.

Is there an oral GLP-1 medication?

Yes. Rybelsus (oral semaglutide) is currently the only FDA-approved oral GLP-1 agonist. Orforglipron, an oral non-peptide GLP-1 agonist, is in late-stage development and may offer a more convenient oral option without the strict fasting requirements of Rybelsus.

Are all GLP-1 medications the same?

No. They differ in their receptor targets (GLP-1 only vs. dual or triple agonism), dosing schedules, delivery methods, approved indications, and efficacy profiles. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide is a pure GLP-1 agonist. These mechanistic differences produce different clinical outcomes.

Can I switch between GLP-1 medications?

Yes, switching is common — usually due to insurance changes, side effects, or inadequate response. Your prescriber will manage the transition, which sometimes involves starting at a lower dose of the new medication and re-titrating. Never switch or adjust dosing on your own.

Do all GLP-1 medications cause nausea?

Nausea is a class effect reported with all GLP-1 agonists. It's most common during dose escalation and typically improves over weeks. The severity varies by medication, dose, and individual tolerance. Eating smaller meals, avoiding fatty foods, and staying hydrated can help manage it.